Last reviewed · How we verify
TNB-738
At a glance
| Generic name | TNB-738 |
|---|---|
| Sponsor | TeneoFour Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNB-738 CI brief — competitive landscape report
- TNB-738 updates RSS · CI watch RSS
- TeneoFour Inc. portfolio CI